Reports Q1 revenue $73.52M, consensus $74.91M. “Our first quarter results illustrate the impact of our commercial focus, which is driving continued market adoption and share gains of our EVO ICL,” said Tom Frinzi, President and CEO of STAAR Surgical. “Our strategic investments in people and processes in recent quarters are now bearing fruit. We are very pleased by the quickening pace of our momentum to start 2024, marked by several significant business milestones, including today’s announcement of the largest-ever practice commitment to EVO ICL in the U.S.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- Staar Surgical names Nancy Sabin CMO, Sisitsky as general counsel
- Staar Surgical price target raised to $53 from $45 at Mizuho
- Staar Surgical price target raised to $46 from $32 at Canaccord
- Staar Surgical upgraded to Outperform after Q1 beat at William Blair
- Staar Surgical upgraded to Outperform from Market Perform at William Blair
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue